April 2024
1. WANG T, Li X, Ma R, Sun J, et al
   Advancements in colorectal cancer research: Unveiling the cellular and molecular mechanisms of neddylation (Review).
   Int J Oncol. 2024;64:39.
   

   >> Share

   
   
2. KAKAFIKA MG, Lyta AA, Gavriilidis GI, Tsiftsoglou SA, et al
   Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K?562 and colorectal HCT?116 cancer cells.
   Int J Oncol. 2024;64:42.
   

   >> Share

   
   
3. SUN J, Chen S, Zang D, Sun H, et al
   Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review).
   Int J Oncol. 2024;64:44.
   

   >> Share

   
   February 2024
4. SHAO C, Han Y, Huang Y, Zhang Z, et al
   Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review).
   Int J Oncol. 2024;64:17.
   

   >> Share

   
   January 2024
5. XIANG L, Wei H, Ye W, Wu S, et al
   Prolyl hydroxylase 2 inhibits glycolytic activity in colorectal cancer via the NF?kappaB signaling pathway.
   Int J Oncol. 2024;64:2.
   

   >> Share

   
   
6. KUMAVATH R, Pavithran H, Paul S, Anju VT, et al
   Effects of gut microbiome and obesity on the development, progression and prevention of cancer (Review).
   Int J Oncol. 2024;64:4.
   

   >> Share

   
   December 2023
7. WANG X, Qu Y, Xing R, Zhou J, et al
   Novel insights into the ecDNA formation mechanism involving MSH3 in methotrexate?resistant human colorectal cancer cells.
   Int J Oncol. 2023;63:134.
   

   >> Share

   
   
8. SAIKI H, Hayashi Y, Yoshii S, Kimura E, et al
   The apelin?apelin receptor signaling pathway in fibroblasts is involved in tumor growth via p53 expression of cancer cells.
   Int J Oncol. 2023;63:139.
   

   >> Share

   
   November 2023
9. MORINAKA T, Sakai N, Takayashiki T, Kuboki S, et al
   RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity.
   Int J Oncol. 2023;63:120.
   

   >> Share

   
   
10. PANTALONE MR, Martin Almazan N, Lattanzio R, Taher C, et al
    Human cytomegalovirus infection enhances 5?lipoxygenase and cycloxygenase?2 expression in colorectal cancer.
    Int J Oncol. 2023;63:116.
    

    >> Share

    
    
11. SUN Q, Liu B, Lan Q, Su Z, et al
    Antimicrobial agent chloroxylenol targets beta?catenin?mediated Wnt signaling and exerts anticancer activity in colorectal cancer.
    Int J Oncol. 2023;63:121.
    

    >> Share

    
    August 2023
12. PARK SY, Seo D, Jeon EH, Park JY, et al
    RPL27 contributes to colorectal cancer proliferation and stemness via PLK1 signaling.
    Int J Oncol. 2023;63:93.
    

    >> Share

    
    
13. KOIZUMI K, Domoto T, Minamoto T, Satomura K, et al
    Deactivation of glycogen synthase kinase-3beta by heat shock‑inducible tumor small protein attenuates hyperthermia‑induced pro‑migratory activity in colorectal cancer cells.
    Int J Oncol. 2023;63:92.
    

    >> Share

    
    July 2023
14. LIU W, Zhang Z, Luo X, Qian K, et al
    m(6)A‑mediated LINC02038 inhibits colorectal cancer progression via regulation of the FAM172A/PI3K/AKT pathway via competitive binding with miR‑552‑5p.
    Int J Oncol. 2023;63:81.
    

    >> Share

    
    May 2023
15. CUI K, Wu H, Zhang L, Li H, et al
    A novel lncRNA 495810 promotes the aerobic glycolysis in colorectal cancer by stabilizing pyruvate kinase isozyme M2.
    Int J Oncol. 2023;62:58.
    

    >> Share

    
    April 2023
16. OH HH, Park YL, Park SY, Joo YE, et al
    A disintegrin and metalloprotease 12 contributes to colorectal cancer metastasis by regulating epithelial‑mesenchymal transition.
    Int J Oncol. 2023;62:50.
    

    >> Share

    
    March 2023
17. CHEN J, Xu J, Yang J, Zhan Y, et al
    alpha‑hederin overcomes hypoxia‑mediated drug resistance in colorectal cancer by inhibiting the AKT/Bcl2 pathway.
    Int J Oncol. 2023;62:33.
    

    >> Share

    
    
18. LIU P, Liu J, Ding M, Liu Y, et al
    FUT2 promotes the tumorigenicity and metastasis of colorectal cancer cells via the Wnt/beta‑catenin pathway.
    Int J Oncol. 2023;62:35.
    

    >> Share

    
    February 2023
19. CHEN Y, Chen M, Deng K
    Blocking the Wnt/beta‑catenin signaling pathway to treat colorectal cancer: Strategies to improve current therapies (Review).
    Int J Oncol. 2023;62:24.
    

    >> Share

    
    January 2023
20. SUI L, Zeng J, Zhao H, Ye L, et al
    Death associated protein3 (DAP3) and DAP3 binding cell death enhancer1 (DELE1) in human colorectal cancer, and their impacts on clinical outcome and chemoresistance.
    Int J Oncol. 2023;62.
    

    >> Share

    
    
21. LEE YJ, Jung E, Choi J, Hwang JS, et al
    The EDN1/EDNRA/beta‑arrestin axis promotes colorectal cancer progression by regulating STAT3 phosphorylation.
    Int J Oncol. 2023;62:13.
    

    >> Share

    
    December 2022
22. RAO X, Lin L
    Circadian clock as a possible control point in colorectal cancer progression (Review).
    Int J Oncol. 2022;61.
    

    >> Share

    
    November 2022
23. PAUL S, Bhardwaj M, Kang SC
    GSTO1 confers drug resistance in HCT116 colon cancer cells through an interaction with TNFalphaIP3/A20.
    Int J Oncol. 2022;61.
    

    >> Share

    
    October 2022
24. DENG Y, Fu H, Han X, Li Y, et al
    Activation of DDX58/RIGI suppresses the growth of tumor cells by inhibiting STAT3/CSE signaling in colon cancer.
    Int J Oncol. 2022;61.
    

    >> Share

    
    September 2022
25. LI M, Xia M, Zhang Z, Tan Y, et al
    METTL3 antagonizes 5FU chemotherapy and confers drug resistance in colorectal carcinoma.
    Int J Oncol. 2022;61.
    

    >> Share

    
    
26. TERADO T, Kim CJ, Ushio A, Minami K, et al
    Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRASactivated pancreatic cancer cells.
    Int J Oncol. 2022;61.
    

    >> Share

    
    June 2022
27. CHANG CC, Kao WY, Liu CY, Su HH, et al
    Butyrate supplementation regulates expression of chromosome segregation 1like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer.
    Int J Oncol. 2022;60.
    

    >> Share

    
    
28. CITRIN D, Valle L, Camphausen K, Cooley-Zgela T, et al
    Pilot trial of topical MTS01 application to reduce dermatitis in patients receiving chemoradiotherapy for stage IIII carcinoma of the anal canal.
    Int J Oncol. 2022;60.
    

    >> Share

    
    
29. ZHAO Q, Long Y, Cheng W, Huang Y, et al
    Visfatin inhibits colon cancer cell apoptosis and decreases chemosensitivity to 5FU by promoting the SDF1/CXCR4/Akt axis.
    Int J Oncol. 2022;60.
    

    >> Share

    
    
30. BRUNO G, Li Bergolis V, Piscazzi A, Crispo F, et al
    TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation.
    Int J Oncol. 2022;60.
    

    >> Share

    
    March 2022
31. ABDULLA M, Traiki TB, Vaali-Mohammed MA, El-Wetidy MS, et al
    Targeting MUCL1 protein inhibits cell proliferation and EMT by deregulating betacatenin and increases irinotecan sensitivity in colorectal cancer.
    Int J Oncol. 2022;60.
    

    >> Share

    
    February 2022
32. WANG J, Yokoyama Y, Hirose H, Shimomura Y, et al
    Functional assessment of miR1291 in colon cancer cells.
    Int J Oncol. 2022;60.
    

    >> Share

    
    
33. CHEN S, Nishi M, Morine Y, Shimada M, et al
    Epigallocatechin3gallate hinders metabolic coupling to suppress colorectal cancer malignancy through targeting aerobic glycolysis in cancerassociated fibroblasts.
    Int J Oncol. 2022;60.
    

    >> Share

    
    
34. BAHR I, Jaeschke L, Nimptsch K, Janke J, et al
    Obesity, colorectal cancer and MACC1 expression: A possible novel molecular association.
    Int J Oncol. 2022;60.
    

    >> Share

    
    
35. PAN S, Deng Y, Fu J, Zhang Y, et al
    N6methyladenosine upregulates miR181d5p in exosomes derived from cancerassociated fibroblasts to inhibit 5FU sensitivity by targeting NCALD in colorectal cancer.
    Int J Oncol. 2022;60.
    

    >> Share

    
    January 2022
36. LIAO Z, Zhang H, Fan P, Huang Q, et al
    [Corrigendum] High PLK4 expression promotes tumor progression and induces epithelialmesenchymal transition by regulating the Wnt/betacatenin signaling pathway in colorectal cancer.
    Int J Oncol. 2022;60.
    

    >> Share

    
    
37. WATANABE K, Shiga K, Maeda A, Harata S, et al
    Chitinase 3-like 1 secreted from cancer-associated fibroblasts promotes tumor angiogenesis via interleukin-8 secretion in colorectal cancer.
    Int J Oncol. 2022;60.
    

    >> Share

    
    December 2021
38. SHI W, Men L, Pi X, Jiang T, et al
    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL6/STAT3 signaling pathway.
    Int J Oncol. 2021;59.
    

    >> Share

    
    March 2021
39. HA THI HT, Duong HQ, Hong S
    Emerging roles of noncoding RNAs in the response of rectal cancer to radiotherapy (Review).
    Int J Oncol. 2021;58:344-358.
    

    >> Share

    
    February 2021
40. ANDO S, Fukamachi K, Yoshimoto E, Matsumoto H, et al
    Palmitoyl piperidinopiperidine, a novel derivative of 10hydroxy2decenoic acid, as a potent and selective anticancer agent against human colon carcinoma cell lines.
    Int J Oncol. 2021;58:251-265.
    

    >> Share

    
    September 2020
41. FENG J, Xiao T, Lu SS, Hung XP, et al
    ANXA1derived peptides suppress gastric and colon cancer cell growth by targeting EphA2 degradation.
    Int J Oncol. 2020 Sep 7. doi: 10.3892/ijo.2020.5119.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share